Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Diabetic Medicine

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Urology

Show all topics

DOI

10.1111/j.1464-5491.2009.02666.x

Other Formats

PDF